Last updated: February 21, 2026
Case Overview
Vifor Pharma, Inc. filed a patent infringement lawsuit against Alkem Laboratories Ltd. in the United States District Court for the District of Delaware. The case number is 1:20-cv-00106, filed on January 17, 2020.
Vifor claims that Alkem infringed on U.S. Patent No. 8,442,085, titled "Methods of Treating Iron Deficiency," issued May 14, 2013. This patent covers formulations and methods related to ferric carboxymaltose, a core component in Vifor’s products used for iron deficiency conditions.
Alkem disputes patent validity and denies infringement, asserting that its generic formulations do not infringe and that the patent claims are invalid due to obviousness and lack of novelty.
Patent Details
- Patent Number: 8,442,085
- Issue Date: May 14, 2013
- Assignee: Vifor (International) Inc.
- Claims: 20 claims covering methods and formulations of ferric carboxymaltose for treating iron deficiency.
Legal Allegations
- Infringement: Alkem’s manufacturing and sale of generic ferric carboxymaltose products infringe upon the '085 patent.
- Patent Validity: The defendant challenges the patent’s validity, citing prior art and alleged obviousness.
- Remedies Sought: Vifor seeks injunctive relief, damages, and attorney fees.
Timeline of Key Events
| Date |
Event |
| Jan. 17, 2020 |
Complaint filed in Delaware District Court |
| Mar. 2, 2020 |
Alkem files answer with affirmative defenses |
| Dec. 2020 |
Patent validity challenges introduced by Alkem |
| Jan. 2021 |
Court orders discovery motions; patent validity and infringement issues debated |
| Nov. 2021 |
Settlement negotiations begin; trial scheduled for 2022 |
Patent Validity Challenges
Alkem asserts the patent should be invalidated on grounds including:
- Obviousness under 35 U.S.C. § 103 due to prior art references.
- Lack of inventive step combining known formulations.
- Publicly available prior research papers dating before the patent’s filing date.
Legal experts note that validity defenses are common in such patent disputes and hinge on prior art references and expert testimony.
Infringement Claims
Vifor contends that Alkem’s generic product, marketed as Iron-C, infringes all asserted claims, especially methods of preparation and specific formulations claimed in the patent. The core issue pertains to whether Alkem’s product matches the patented specifications or employs a substantially similar formulation.
Patent Litigation Strategy
Vifor relies on the strength of its patent portfolio and the uniqueness of its ferric carboxymaltose formulations. It aims for injunctive relief to prevent Alkem from marketing its generic version until patent expiration or invalidation.
Alkem’s defense emphasizes the argument that the patent claims are either anticipated or rendered obvious by prior art, seeking to invalidate key claims to enable generic entry.
Implications and Industry Context
The outcome impacts the iron supplement market, especially as the U.S. generic market seeks to introduce cheaper alternatives to Vifor’s branded therapies. The case exemplifies the ongoing patent battles in specialty pharmaceuticals, balancing patent protections with generic drug entry.
Patent litigation in this sector often results in extended legal battles, with potential for settlement or licensing agreements if infringement or validity is disputed.
Key Takeaways
- The case centers on the validity and infringement of a patent covering ferric carboxymaltose formulations.
- Alkem challenges both patent enforceability and infringement, seeking a broad invalidation.
- Vifor’s strategic goal is to maintain market exclusivity through injunctive relief while defending the patent’s validity.
- The case highlights the tension between patent rights and generic market entry in specialty drugs.
- Resolution may involve a settlement, patent invalidation, or continued litigation, with significant market repercussions.
FAQs
1. What triggers a patent infringement lawsuit in pharma?
When a generic manufacturer launches a product that falls within the scope of a patented formulation or method without authorized licensing, the patent owner can initiate legal action for infringement.
2. How does validity challenge affect patent enforcement?
If a court finds the patent invalid, the infringement claim fails, allowing generic entry without penalty or damages.
3. What are common defenses in pharma patent litigation?
Defendants often argue prior art anticipation, obviousness, or that the patent claims are indefinite or lack novelty.
4. How do patent disputes impact drug pricing?
Successful enforcement extends exclusivity, delaying generic competition, and typically maintaining higher drug prices until patent expiry or invalidation.
5. When can a settlement occur in patent litigation?
Parties settle when they reach agreements such as licensing, cross-licensing, or consent judgments, often to avoid costly trial processes.
References
- Court docket, Vifor Pharma, Inc. v. Alkem Laboratories Ltd., No. 1:20-cv-00106 (D. Del., 2020).
- United States Patent and Trademark Office. (2013). Patent No. 8,442,085.
- Federal Trade Commission. (2022). Patent Litigation and Market Competition.
- Food and Drug Administration. (2020). Guidelines on Generic Drug Approvals.
- Kesselheim, A. S., et al. (2017). Patent Litigation and Generic Entry in the United States. New England Journal of Medicine, 376(22), 2115–2124.
